Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

Packaging firm PCI buys Welsh CDMO for $215m

PCI’s CEO Bill Mitchell told Outsourcing-Pharma.com he plans to have the two firms continue to operate as distinct companies

Packaging Coordinators Inc (PCI) has announced its acquisition of Welsh contract development and manufacturing organisation (CDMO) Penn Pharmaceutical Services in a £127m ($215m) deal.

Related news

News in brief

Increased emphasis on global clinical trials is promoting consolidation of contract research organisations (CROs), according to an industry report by M&A services firm 11T Partners.

SRI International was awarded a seven-year, $49m contract from the NIAID (National Institute of Allergy and Infectious Diseases), which is a division of the NIH (National Institutes of Health), for preclinical HIV/AIDS work.

Strategic partnerships are “flexible, cost-effective and will become the trend over the next few years,” says CRO DZS, which has signed a multi-year deal with SBI Pharmaceuticals.

Hikma has bought defunct manufacturer Ben Venue and says it could reactivate the site in the long-term, despite the transfer of equipment across its sterile injectables network.

Global Industry News

Anti-addiction film resilient to generics, says Reckitt Benckiser from in-PharmaTechnologist.com

Reckitt Benckiser’ opioid addiction drug Suboxone delivered by sublingual film has shown a 'surprising' level of resilience against generic competition, the firm says as it plans to spin-out its pharmaceutical business.

Biocon: Political turmoil hits sales, but quality systems ensure future from in-PharmaTechnologist.com

Robust quality systems differentiate Biocon from other Indian manufacturers, the firm says, despite political turmoil in the Middle East and North Africa impacting first quarter 2015 sales.

First come, first served? FDA may allow reservation of drug names from in-PharmaTechnologist.com

The US Food and Drug Administration (FDA) is inviting public comment on plans to allow drug companies to reserve proprietary names for medicines as early as the end of Phase II trials.

UK Gov should seek licenses for off-patent drugs in new indications says MP from in-PharmaTechnologist.com

The UK Government should seek licenses to use off-patent drugs in new indications according to MPs who say there is no incentive for pharma firms to apply for such approvals after a product goes generic.

Waters broadens mass spec offering with REIMS acquisition from in-PharmaTechnologist.com

Analytic science company Waters has acquired all of the assets of MediMass, which includes its Rapid Evaporative Ionization Mass Spectrometry (REIMS) technology, as well as patent applications, software, databases and REIMS expertise.

PaxVax acquires typhoid vaccine, Swiss manufacturing facility from BioPharma-Reporter.com

Specialty vaccine company PaxVax has acquired the oral typhoid vaccine Vivotif from Crucell, as well as its manufacturing facility in Thörishaus, Switzerland. Financial terms of the transaction were not disclosed.

Boehringer Ingelheim forges $395m peptide deal with Zealand from BioPharma-Reporter.com

Boehringer Ingelheim has entered a collaboration to develop a peptide candidate for cardio-metabolic diseases in a deal that could net partner Zealand Pharma up to €295m ($395m).

Spotlight

Petition calls on FDA to amend informed consent requirements

Petition calls on FDA to amend informed consent requirements

The Center for Responsible Science  has asked the US FDA to adopt informed consent rules which ensure that trial participants...

US FDA to set more specific GMP regulations for outsourcing facilities

US FDA to set more specific GMP regulations for outsourcing facilities

Until final regulations are finished, the US FDA has released draft guidance describing the agency’s expectations for...

Parexel taps Middle East, North Africa with Atlas acquisition

Parexel taps Middle East, North Africa with Atlas acquisition

CRO Parexel has shifted its attention overseas with the acquisition of Atlas Medical Services, a provider of...

Trial documents: only 13% of firms are fully paperless, says Veeva

Trial documents: only 13% of firms are fully paperless, says Veeva

Contract research organisations (CROs) have been slow to adopt next-generation means of recording study documents, with only...

Pfizer offers update on risk-sharing deals with Icon, Parexel
Dispatches from DIA

Pfizer offers update on risk-sharing deals with Icon, Parexel

Three years after Pfizer began strategic partnerships with CROs Icon and Parexel, and the companies are still...

Key Industry Events

 

Access all events listing

Our events, Events from partners...